MET and small cell lung carcinoma: In addition to the drug resistance conferred by the C797S mutation in EGFR, amplification of the MET gene as a bypass pathway, alteration in RAS-RAF-MAPK pathway, ROS1 fusion gene, PIK3CA mutation, and transformation to small cell lung cancer are other mechanisms that impart drug resistance.